Fibroblast Growth Factor (FGF) signaling promotes self-renewal in progenitor cells by encouraging proliferation and inhibiting cellular senescence. Yet, these beneficial effects can be hijacked by disease-causing mutations in FGF receptor (FGFR) during embryogenesis. By studying dominant FGFR2 mutations that are germline in bent bone dysplasia syndrome (BBDS), we reveal a mechanistic connection between FGFR2, ribosome biogenesis, and cellular stress that links cell fate determination to disease pathology. We previously showed that FGFR2 mutations in BBDS, which amplify nucleolar targeting of FGFR2, activate ribosomal DNA (rDNA) transcription and delay differentiation in osteoprogenitor cells and patient-derived bone. Here we find that the BBDS mutations augment the ability of FGFR2 to recruit histone-remodeling factors that epigenetically activate transcriptionally silent rDNA. Nucleolar morphology is controlled by chromatin structure, and the high levels of euchromatic rDNA induced by the BBDS mutations direct nucleolar disorganization, alter ribosome biogenesis, and activate the Rpl11-Mdm2-p53 nucleolar stress response pathway. Inhibition of p53 in cells expressing the FGFR2 mutations in BBDS rescues delayed osteoblast differentiation, suggesting that p53 activation is an essential pathogenic factor in, and potential therapeutic target for, BBDS. This work establishes rDNA as developmentally regulated loci that receive direct input from FGF signaling to balance self-renewal and cell fate determination.
Introduction
Ribosomes direct the catalytic steps necessary to translate all cellular mRNAs into proteins within a cell. A mammalian cell may have as many as 10 million ribosomes with each ribosome containing 4 ribosomal RNAs (rRNA) associated with 80 ribosomal proteins (RPs) (1) . Thus, ribosome biogenesis is a metabolically demanding process that is highly responsive to developmental and environmental cues, adapting to meet variable needs for protein production. The regulatory mechanisms for ribosome biogenesis primarily act at the $400 mammalian rRNA gene repeats (rDNA) that are transcribed under the control of RNA Polymerase I (RNA Pol I), a dedicated set of transcription factors including UBF1, and regulators of chromatin structure (2) (3) (4) (5) .
Transcription of rDNA by RNA Pol I is considered a ratelimiting step in ribosome production (1, 2, 6) and dynamically regulated throughout cell ontogeny by signals that control selfrenewal and differentiation (7) (8) (9) . While proliferation and selfrenewal are associated with elevated rDNA transcription, differentiation signals induce stem and progenitor cells to down-regulate rDNA transcription (10, 11) . Consistent with this idea, we showed that differentiation signals induce osteoprogenitor cells to transiently silence a subset of rDNA through biphasic nucleolar depletion of UBF1 followed by RNA Pol I (12) . The silencing of rDNA during differentiation is initiated by lineage-specific transcription factors that directly interact at the rDNA promoter and recruit histone deacetylases (HDACs) and methyltransferases to command a heterochromatin switch (13, 14) . In osteoprogenitor cells, this lineage-specific factor is RUNX2, the master regulator of osteoblast differentiation (15, 16) . While the tissue-specific factors that direct rDNA silencing in multiple committed cell-types including osteoblasts are slowly being uncovered, the upstream regulators that establish and maintain relatively high levels of active rDNA in progenitor cells remain elusive.
We previously identified the Fibroblast Growth Factor (FGF) signaling pathway as a direct activator of rDNA transcription in osteoprogenitor cells. By studying the pathophysiology of bent bone dysplasia syndrome (BBDS; MIM 614592), a congenital skeletal disorder characterized by a deficiency in osteoblasts despite a rich supply of osteoprogenitor cells, we discovered that FGF receptor-2 (FGFR2) directly activates rDNA transcription from within the nucleolus (17, 18) . Our results showed that FGFR2 occupies the rDNA promoter where it interacts with FGF2 and UBF1 to limit transcriptional repression by RUNX2. We found that the BBDS associated mutations p.M391R and p.Y381D in FGFR2 enhance nucleolar localization of the receptor and augment its activity. Correspondingly, bone tissue from BBDS patients exhibit significantly increased levels of pre-rRNA compared with stage-matched controls. Furthermore, we demonstrated that high levels of rDNA transcription induced by p.M391R and p.Y381D mutations hold osteoprogenitor cells in a self-renewing state and delay their differentiation into osteoblasts. Thus, our data strongly support the conclusion that increased ribosome biogenesis is, at least in part, responsible for the skeletal phenotype in BBDS.
While BBDS is the first congenital disorder to be associated with elevated levels of ribosome biogenesis, multiple congenital disorders, known as ribosomopathies, are associated with deficient ribosome production (19) . In ribosomopathies, mutations in RPs or factors necessary for the synthesis of mature rRNA lead to an imbalance in the stoichiometry of ribosome components that inhibit assembly, stability, and fidelity of 40S and 60S subunits. These perturbations in ribosome biogenesis lead to the activation of the p53 nucleolar stress response pathway. During nucleolar stress, non-ribosome bound 'free' RPs, including Rpl5 and Rpl11, bind to and inhibit Mdm2, an E3 ubiquitin ligase that promotes p53 degradation (20) (21) (22) (23) . Inhibition of Mdm2, in turn, allows for nuclear accumulation of p53. Genetic models for ribosomopathies have shown that allele reduction of p53 either partially or completely rescues their phenotypes (24) (25) (26) (27) (28) (29) . While these studies demonstrate a seminal role for the Rpl11-Mdm2-p53 pathway in disorders with deficient ribosome biogenesis, involvement of this surveillance mechanism in congenital disorders with elevated ribosome production, and specifically in BBDS, is unclear (18) .
To better understand the pathogenesis of BBDS, we investigated how FGFR2 activates rDNA transcription and the extent to which the BBDS mutations impact this nucleolar function in osteoprogenitor cells. We find that FGFR2 switches the epigenetic state of rRNA genes from poised to active by recruiting B-WICH, P300, and UBF1 to the rDNA promoter. FGFR2-mediated activation of rRNA genes in turn increases ribosome production.
The p.M391R and p.Y381D mutations in BBDS uniquely recruit Cockayne syndrome protein B (CSB), in addition to P300 and B-WICH, to enhance FGFR2-mediated activation of rRNA genes. Pathological increase in euchromatic rDNA triggered by p.M391R and p.Y381D mutations in FGFR2 coincides with abnormal nucleolar morphology, altered ribosome production, and activation of the Rpl11-Mdm2-p53 stress response pathway. Since p53 is a known inhibitor of osteoblast differentiation, its activation can explain a molecular mechanism through which the BBDS mutations delay differentiation in osteoprogenitor cells (18, 30, 31) . Indeed, we show pharmacological inhibition of p53 rescues differentiation in osteoprogenitor cells that express p.M391R and p.Y381D mutations in FGFR2. Collectively, this suggests that p53 activation is an essential pathogenic factor in BBDS and a potential target for the therapeutic prevention of BBDS.
Results

FGFR2 converts the epigenetic signature of rDNA from poised to active
We previously showed that FGFR2 directly promotes rDNA transcription in MC3T3-E1 osteoprogenitor cells and that this transactivation potential is enhanced by the FGFR2 mutations p.M391R and p.Y381D in BBDS (18) . The relative amounts of transcriptionally active and silent rRNA genes are dynamically regulated throughout cell ontogeny by epigenetic mechanisms (32, 33) . Thus, we predicted that FGFR2 activates rDNA transcription by increasing the relative number of rRNA genes with an active epigenetic signature. To assess the effects of FGFR2 on the epigenetic signature of rDNA, we performed ChIP-qPCR in MC3T3-E1 mouse calvarial osteoprogenitor cells stably transduced with lentiviral vectors that express equivalent levels of FGFR2, FGFR2 (18) .
Epigenetically active rDNA is demarcated, in part, by histone lysine acetylation (ac). ChIP analysis along the rDNA repeat showed that FGFR2 increased H3K14ac, H3K9ac, and H3K27ac within the upstream core enhancer (UCE) region of the promoter compared with the untransduced control ( Fig. 1A-C rDNA or other independent genomic loci such as Actin and Gapdh (Supplementary Material, Fig. S1E and F). Silencing of rDNA is mediated by the nucleolar-remodeling complex (NoRC), which recruits HDACs and DNA methyltransferases to establish the structural characteristics of heterochromatin (36, 37 FGFR2 promotes 'active' positioning of the promoterbound nucleosome
Once rDNA acquires active histone marks, movement of the promoter-bound nucleosome to the 'on' position is the next key step for transcriptional activation. Thus, active and poised rDNA differ in the positioning of the promoter-bound nucleosome. In active rDNA, the promoter-bound nucleosome is in the 'on' position covering nucleotides À157 to À2, leaving the transcription start site (TSS) exposed. In transcriptionally silent and poised rRNA genes, the nucleosome is in the 'off' position covering nucleotides À132 to þ22, preventing assembly of the RNA Pol I pre-initiation complex at the TSS (38, 39) . We previously showed that FGFR2 interacts with the rDNA promoter at the UCE, a region adjacent to the TSS (18) . To determine the influence of FGFR2 on the position of the promoter-bound nucleosome at the rDNA TSS, we used the DNA footprint assay nucleosome occupancy and methylome assay (NOMe)-seq. In NOMe-seq, a GpC methyltransferase is used to methylate GpC dinucleotides not protected by nucleosomes, which are subsequently detected by bisulfite conversion and sequencing to generate a footprint of chromatin accessibility (40) . Our NOMe-seq analysis surveyed the sequence 416 bp upstream and 10 bp downstream of the rDNA TSS, with each clone representing an individual rDNA promoter with a unique chromatin configuration from a population of osteoprogenitor cells. In control cells, the promoter-bound nucleosome was in the 'on' position in 58% (11 of 19) of rDNA clones ( Fig. 2A) . FGFR2 slightly increased the number of rDNA clones with accessible TSS to 60% (14 of 23, P ¼ 0.20) (Fig. 2B) (46, 47) . Histone acetylation by HATs such as PCAF and P300 is critical for transcriptional activation of rDNA (48, 49) . We found that FGFR2, FGFR2
M391R
, and FGFR2 Y381D increased occupancy of P300 in the UCE compared with control ( Fig. 3C ). FGFR2
M391R and FGFR2 Y381D also increased P300 occupancy in the 5'-ETS and 28S coding region (Fig. 3C ). While CSB has been shown to recruit PCAF, the factor that directly recruits P300 to rDNA is unknown (47) . Immunoprecipitation from control osteoprogenitor cell extracts identified protein interactions between P300 and the wild-type and mutant forms of FGFR2. This suggests that FGFR2 is directly involved in rDNA recruitment of P300 (Fig. 3D ). UBF1 is a specialized architectural transcription factor for RNA Pol I that binds the UCE of rDNA to activate transcription (3, 33) . We previously showed that FGFR2 interacts with UBF1 at the UCE and other UBF1-binding sites along the rDNA repeat in osteoprogenitor cells (18) . We also showed that nucleolar localization of UBF1 is associated with relatively higher levels of rDNA transcription in osteoprogenitor cells and that nucleolar depletion of UBF1 is coincident with a sharp decrease in rDNA transcription during osteoblast differentiation (12) . FGFR2, FGFR2
, and FGFR2 Y381D increased occupancy of UBF1 at the UCE compared with control ( Fig. 3E ). FGFR2 M391R and FGFR2
Y381D
further enhanced UBF1 occupancy within the coding region of the 28S, a region we showed previously to be occupied by endogenous FGFR2 and UBF1 ( Fig. 3E ) (18) . UBF1 initiates formation of the RNA Pol I pre-initiation complex at the UCE by recruiting the SL1 initiation complex, which includes the TATA box-binding protein TBP (3). The SL1 complex then recruits an initiationcompetent subpopulation of RNA Pol I (50-52). FGFR2 M391R and FGFR2 Y381D enhanced occupancy of TBP and RNA Pol I at the UCE suggests increased promoter loading of the RNA Pol I preinitiation complex ( Fig. 3F and G).
p.M391R and p.Y381D mutations disrupt nucleolar morphology during osteoblast differentiation
The size and shape of nucleoli are robust indicators of nucleolar activities including rDNA transcription (53) . Active nucleoli are composed of fibrillar cores (FCs) surrounded by granular components (GCs) (54) ; the FCs are the sites of rDNA transcription and rRNA processing while GCs are the sites of pre-ribosome assembly (55) . Active rDNA is contained within the FCs with RNA Pol I, while most silent heterochromatic rDNA is held at the nucleolar periphery, contributing to the dense perinucleolar chromatin (56) . We showed previously that the nucleoli of osteoprogenitor cells undergo reorganization during osteoblast differentiation (12) . We also found that high levels of rDNA transcription induced by the BBDS mutations are linked to delayed osteoblast differentiation (18) . To examine the dynamics of nucleolar structure during osteoblast differentiation, we performed immunofluorescence staining for RNA Pol I in osteoprogenitor cell lines on Days 0 and 2 of osteoinduction. The nucleoli of undifferentiated osteoprogenitor cells were compact with an inner core of RNA Pol I surrounded by dense perinucleolar chromatin ( Fig. 4A and A 0 ). After 2 days in osteogenic medium, the nucleoli of differentiating cells underwent reorganization, reducing in size and RNA Pol I content (Fig. 4E ). This is consistent with our previous findings that reduction in nucleolar RNA Pol I coincides with a marked decrease in rDNA transcription by Day 3 of osteoblast differentiation (12) . Upon inhibition of rDNA transcription, FCs and GCs segregate, and the RNA Pol I transcription machinery is redistricted to small nucleolar caps (57) .
In differentiating control cells at Day 2, RNA Pol I was localized to small nucleolar caps peripheral to the central body and also foci dispersed throughout the cytoplasm ( and hypertrophic nucleoli result from specific loss of silent rDNA genes, leading to enlarged and irregular morphology (58) . Interestingly, this nucleolar morphology is indicative of high levels of rDNA transcription found in malignant cells (59) . Reticular nucleoli in FGFR2
M391R
-and FGFR2
Y381D
-expressing cells were associated with loss or invasion of perinucleolar chromatin, which normally surrounds the nucleolar body ( Fig.  4C and D) . In some cases, nucleoli were dispersed throughout the nuclear interior, forming nucleolar 'necklaces' that are known to result from highly extended linear arrays of rDNA (Fig. 4C, Since absolute levels rather than relative fluctuations of 45S pre-rRNA could be a critical factor in osteoblast differentiation, we also examined the absolute levels of 45S pre-rRNA and Osteocalcin expression (Supplementary Material, Fig. S3A and B) . This analysis identified similar expression trends, and taken together, suggests that the BBDS mutations concurrently alter 
WB: anti-P300 2% Input V5 were collected for immunoprecipitation with anti-V5 followed by immunoblotting of P300. A representative western blot from three biological replicates is shown.
ChIP-qPCR analyses indicate occupancy of (E) UBF1 along the rDNA repeat and (F) TBP and (G) RNA Polymerase I (RNA Pol I) at the UCE. ChIP enrichment was determined as a percentage of the input. Error bars represent the SEM from 3 biological replicates.
the transcriptional profiles for rDNA and osteoblast-specific genes during osteoinduction.
Inhibition of RNA Pol I does not rescue delayed osteoblast differentiation induced by p.M391R and p.Y381D mutations
We previously showed that the elevated rRNA gene transcription induced by FGFR2 M391R and FGFR2 Y381D is coincident with diminished osteoblast differentiation compared with FGFR2 ( Fig. 5C ) (18) . Evidence suggests that decreased rDNA transcription is intimately tied to differentiation in multiple cell types (9, 11, 13, 63, 64 Fig. S4 and B) . Alkaline phosphatase (AP) staining following treatment with Act. D (750 nM), which selectively inhibits RNA Pol I elongation at low concentrations, completely blocked osteoblast differentiation in all osteoprogenitor cells (Fig. 5D) (60, 65, 66) . Since Act. D can also target other RNA polymerases, we treated cells with CX-5461 (150 nM), a small-molecule inhibitor of rDNA transcription that specifically blocks RNA Pol I initiation (67) . We customized the dose of CX-5461 to lower 45S pre-rRNA levels in osteoprogenitor cells expressing FGFR2, FGFR2
M391R
, and FGFR2 Y381D on Day 3 to the levels seen in control cells ( Fig. 5F ; Supplementary Material, Fig. S3C ). Similar to Act. D, CX-5461 treatment blocked osteoblast differentiation as detected by AP staining and Osteocalcin expression ( Fig. 5E and G; Supplementary Material, Fig. S3D ). Thus, a decrease in rDNA transcription does not rescue differentiation in cells expressing FGFR2 M391R and FGFR2 Y381D but rather blocks osteoblast differentiation in all osteoprogenitor cells. From these data, we conclude that a quantitative increase in rDNA , and FGFR2 Y381D increased the synthesis of the 40S and 60S ribosomal subunits as well as the 80S ribosomes and polysomes in osteoprogenitor cells compared with control MC3T3-E1 cells (Fig. 6A-C) . Areas under the curve were measured on polysome profile graphs from 4 biological replicates for control, FGFR2, FGFR2
, and FGFR2 Y381D and average fold-differences calculated (Table 1) . FGFR2-expressing cells had a 1.41-fold increase in 40S, 1.86-fold increase in 60S, and 1.27-fold increase in 80S relative to control ( Fig. 6A ; Table 1 ). FGFR2
-expressing cells had a 1.27-fold increase in 40S, 1.28-fold increase in 60S, and 1.53-fold increase in 80S compared with control ( Fig. 6B ; Table  1 ). Similarly, FGFR2
Y381D -expressing cells had a 1.33-fold increase in 40S, 1.18-fold increase in 60S, and 1.75-fold increase in 80S compared with control ( Fig. 6C ; Table 1 ). These results higher compared with that of FGFR2 (1.14) ( Table 1) . Maintenance of free 40S and 60S pools are critical for translation initiation, as the 40S is assembled into the 43S pre-initiation complex and loaded onto mRNA prior to the association with the 60S subunit. Deficiencies in factors that prevent nonproductive association of free 40S and 60S subunits increase the ratio of 80S monosomes to free ribosomal subunits (68) (69) (70) (71) . Therefore, that FGFR2 M391R and FGFR2 Y381D increase the ratios of 80S monosomes to free ribosomal subunits indicate deregulated ribosome assembly.
Mutations p.M391R and p.Y381D activate the p53 nucleolar stress response pathway
Altered nucleolar morphology and abnormities in ribosome biogenesis can lead to nuclear stress (53). Our observation that FGFR2 M391R and FGFR2 Y381D alter nucleolar structure as well as ribosome biogenesis led us to examine the possibility of nucleolar stress. Nucleolar stress is characterized by the non-ribosome bound 60S RP Rpl11 that binds to and inhibits the principal antagonist of p53, Mdm2 (20) (21) (22) (23) . Mdm2 is an E3 ubiquitin ligase that promotes proteasome degradation of p53. In unstressed cells, most of the p53 pool is ubiquitinated and localized to the cytoplasm (72) . Upon nucleolar stress, inhibition of Mdm2 by Rpl11 enhances p53 nuclear accumulation.
In control osteoprogenitor cells, immunofluorescence showed that p53 was largely restricted to the cytoplasm (Fig.  7A) . FGFR2 did not alter cytoplasmic localization of p53 ( 
Inhibition of aberrant p53 activation rescues delayed osteoblast differentiation
The tumor suppressor protein p53 plays a critical role in nucleolar stress: impaired ribosome biogenesis and/or disruption to nucleolar structure results in p53 activation (73) (74) (75) . Activation of p53 in response to nucleolar stress leads to the transactivation of p53-target genes, including p21 WAF1 (20, 76) . To determine the level of p53 activation during osteoblast differentiation, we examined expression of p21 WAF1 by qRT-PCR and normalized to the cells' respective levels on Day 0. By Day 3, control osteoprogenitor cells showed a 2.7-fold increase in p21 WAF1 (Fig. 9A) . FGFR2 decreased the fold activation of p21 WAF1 expression to 1.9-fold, suggesting even less p53 activity compared with control (Fig. 9A) . In comparison, FGFR2 M391R and FGFR2 Y381D increased the activation of p21 WAF1 expression to 4.8-and 5.2-fold, respectively, on Day 3 (Fig. 9A) . These results further suggest that the BBDS mutations activate p53 during osteoblast differentiation. In ribosomopathies with decreased ribosome biogenesis, the Rpl11-Mdm2-p53 nucleolar stress response pathway is activated, and down-regulation of aberrant p53 activation can either partially or completely rescue the phenotypes in animal models (24) (25) (26) (27) (28) (29) 77, 78) . Furthermore, p53 is known to negatively regulate osteoblast differentiation (30, 31 , and FGFR2 Y381D without altering cell viability ( Fig. 9B; Supplementary Material, Fig. S4C ). In control cells, pifithrin-a treatment did not alter osteogenic differentiation, as detected by AP activity (Fig. 9C and D) . Furthermore, pifithrin-a treatment did not alter the ability of FGFR2 to enhance osteoblast differentiation ( Fig. 9C and D) . On the other hand, pifithrin-a rescued deficient osteogenic differentiation induced by FGFR2 M391R and FGFR2
Y381D
and brought AP staining to intensities similar to FGFR2 ( 
Discussion
This study advances our understanding of the disease mechanisms for BBDS, a congenital FGFR2-disorder with severe delays B C D Figure 7 . The BBDS mutations lead to nuclear accumulation of p53. Control MC3T3-E1 and stable cell lines expressing FGFR2, FGFR2 M391R , and FGFR2 Y381D were exposed to doxycycline (250 ng/ml) for 2 days to induce receptor expression prior to immunofluorescence for anti-p53 (red) and counterstaining with DAPI (white).
Representative immunofluorescent confocal images (63Â plus 1.5Â digital zoom) of (A) control MC3T3-E1 cells and stable cell lines expressing (B) FGFR2, (C) in osteoblast differentiation. By studying this rare skeletal disorder, we have delineated a nucleolar role for FGFR2 in regulating cell fate determination in osteoprogenitor cells. Here we show that nucleolar FGFR2 epigenetically activates transcriptionally silent rDNA by recruiting histone modifiers and chromatin remodelers. We also demonstrate that the BBDS mutations in FGFR2 p.M391R and p.Y381D augment the ability of FGFR2 to epigenetically activate rDNA. We showed previously that the BBDS mutations, which reside within the transmembrane helix, disrupt plasma membrane association of the receptor and consequently, amplify the receptor's normal nucleolar targeting (17, 18) . Therefore, evidence suggests that BBDS mutations interfere with mechanisms that regulate subcellular localization of FGFR2. Increased levels of nucleolar FGFR2, in turn, promote high levels of euchromatic rDNA, block nucleolar reorganization, and rDNA silencing that normally occur during osteoblast differentiation. We found that deregulated epigenetic activation of rDNA disrupts nucleolar structure and subsequently alters ribosome biogenesis and activates the Rpl11-Mdm2-p53 nucleolar stress response pathway. p53 is a known inhibitor of osteoblast differentiation, and we showed that its inhibition rescues delayed differentiation in osteoprogenitor cells expressing the BBDS mutations. We expect that enhanced nucleolar targeting of wild-type FGFR2 would results in a similar response. This is supported by our in ovo studies that show expression of FGFR2 fused to a synthetic nucleolar localization signal in the limb mesenchyme of avian embryos induces a skeletal phenotype that overlaps with BBDS (our unpublished data). We determined that nucleolar FGFR2 epigenetically activates transcriptionally silent rDNA by recruiting B-WICH, P300, and UBF1. We also showed that the p.M391R and p.Y381D mutations enhance the normal activity of FGFR2 to epigenetically activate rDNA by increasing recruitment of not only B-WICH, P300, and UBF1, but also CSB. That the BBDS mutations selectively recruit CSB is likely a fundamental step to augment transcriptional activation of rDNA: CSB promotes epigenetic activation of rDNA by directly recruiting histone acetylases and acts synergistically with B-WICH (41, 46, 47, 79) . Increased occupancy of CSB in osteoprogenitor cells expressing FGFR2 M391R and FGFR2 Y381D can therefore explain enriched levels histone acetylation and P300. CSB also promotes transcriptional activation of rDNA by directly interacting with the RNA Pol I transcription initiation complex (43, 44) . This is supported by selective enrichment of RNA Pol I in cells expressing the BBDS mutations. Interestingly, inactivating mutations in CSB, which reduce RNA Pol I recruitment and inhibit 45S pre-rRNA synthesis, are responsible for Cockayne's syndrome, a progeroid-like disorder with facial dysmorphism and skeletal abnormalities (43, 44, (80) (81) (82) (83) . This suggests that the role of CSB at rDNA is particularly important in developing bone. The epigenetic state of rDNA is a critical determinant of nucleolar structure. We also showed that FGFR2 M391R and FGFR2 Y381D decreased the occupancy of silent histone marks including H3K9me2 and H3K27me3. Silent heterochromatic rDNA arrays associate with the perinucleolar centromeric chromatin, whereas active rDNA arrays project into the nucleolar space. Impaired silencing of rDNA prevents formation of the perinucleolar heterochromatin, and subsequent loss of silent rDNA arrays disrupts nucleolar morphology (58, 84, 85) . For example, reduction in histone de-acetylation or H3K9 methylation at rDNA leads to disorganization of the nucleolar compartments and fragmentation (58, 86) . We found that in cells expressing FGFR2 M391R and FGFR2
Y381D
, reduced H3K9me2 occupancy was associated with disruptions in perinucleolar chromatin and invading DAPI-positive projections in the nucleolar space. This is evidence that FGFR2 M391R and FGFR2 Y381D disrupt nucleolar organization and integrity by reducing the amount silent rDNA arrays. Upon osteoinduction, the nucleoli of normal differentiating cells undergo reorganization, depleting first UBF1 and then RNA Pol I (12) . This nucleolar reorganization induces transient silencing of rDNA transcription and is associated with increased expression of osteoblast-specific genes and cell cycle withdrawal (12, 13, 15) . Here we found that p.M391R and p.Y381D mutations in FGFR2 block nucleolar reorganization and RNA Pol I, maintain high levels of rDNA transcription, and repress expression of osteoblast-specific genes following osteoinduction. We previously showed that high levels of rDNA transcription induced by the BBDS mutations are linked to delayed differentiation in osteoprogenitor cells (18) . The level of rDNA transcription correlates with the state of cellular differentiation, whereby selfrenewing progenitor cells synthesize higher levels of rRNA compared with their terminally differentiated progeny (13, 87, 88) . Differentiation signals induce progenitor cells to down-regulate relatively higher levels of rDNA transcription in order to produce differentiated progeny, indicating a functional importance for this relationship (10, 11 ). Yet pharmacological inhibitors of RNA Pol I were not sufficient to rescue delayed osteoblast differentiation in cells expressing FGFR2 M391R and FGFR2
. However, we are unable to conclude that levels of rDNA transcription do not directly effect osteoblast differentiation because RNA Pol I inhibitors induce p53-mediated cellular stress (89, 90) . Nevertheless, we provide evidence that the epigenetic state of rDNA, which is an upstream determinant of rDNA transcription levels, is critical for cell fate. Chromatin organization plays a structural role in nucleolar function and epigenetic silencing of rDNA is likely a prerequisite for nucleolar reorganization during osteoblast differentiation. That wild-type FGFR2 enhances rDNA transcription and yet also allows for nucleolar reorganization during osteoblast differentiation supports this conclusion.
Nucleolar morphology is determined by the activity of ribosome biogenesis, and dramatic changes in nucleolar structure often coincide with disruptions in ribosome biogenesis (53, 91, 92) . Large and disorganized nucleoli in osteoprogenitor cells expressing FGFR2 M391R and FGFR2 Y381D were coincident with increased ribosome production, as well as altered ratios of 80S monosomes to free 40S and 60S ribosomal subunits. Maintenance of free 40S and 60S pools are critical for translation initiation, as the 40S is assembled into the 43S pre-initiation complex and loaded onto mRNA prior to 60S joining (93) . Multiple factors, including eukaryotic initiation factors, maintain the equilibrium between 80S and the free ribosomal subunits by preventing non-productive association of 40S and 60S into empty 80S ribosomes (93) . These regulatory factors have limited abundance and, when deficient, increase the ratio of 80S monosomes to free ribosomal subunits (68) (69) (70) (71) . Since the 80S ribosome peak includes mRNA-bound and free ribosomes, an increase in 80S peak, as well as a decrease in the relative levels of 40S and 60S subunits to 80S ribosomes, suggests that FGFR2 M391R and FGFR2 Y381D alter ribosome biogenesis by promoting formation of 'empty' 80S ribosomes. Disruptions to nucleolar structure and ribosome biogenesis activate the p53 nucleolar stress response pathway (20, 63, (94) (95) (96) . Select 60S ribosomal subunit proteins, including Rpl11 and Rpl5, monitor nucleolar stress and are strong effectors of p53 steady-state levels (92) . Breakdown in nucleolar structure or a stoichiometric imbalance in ribosomal components trigger release of Rpl11 and Rpl5 into the nucleoplasm, where they interact with Mdm2 to inhibit Mdm2-mediated degradation of p53 (74, 96, 97) . In ribosomopathies where there is a stoichiometric imbalance in ribosomal components, increased availability of Rpl11 leads to high levels of p53 activation (77) . On the other hand, an overall balanced increase in ribosome biogenesis reduces ribosome-free Rpl11 and therefore diminishes p53 activation (98) . Here we showed that the BBDS mutations, which increase ribosome biogenesis, trigger Rpl11-mediated inhibition of Mdm2 and lead to p53 activation in osteoprogenitor cells. This suggests that the BBDS mutations increased availability of non-ribosome bound Rpl11 by altering nucleolar structure and/ or ribosome biogenesis.
We present evidence that abnormal nucleolar structure and/ or imbalance in ribosome biogenesis regulates osteoblast differentiation through its nearly inseparable connection with the p53 nucleolar stress response pathway. The cellular response to p53 accumulation is dependent on multiple factors including cell type, intensity, and duration of the stress signal, level of p53 expression, oncogenic dependency, as well as expression of growth and survival factors (99) . In animal models for ribosomopathies, apoptosis is a strong contributor to the embryonic phenotypes, which can be either partially or completely rescued by blocking p53 (24) (25) (26) (27) (28) (29) . Although the BBDS mutations activate p53 in osteoprogenitor cells, we have found no clear evidence of apoptosis or senescence. Rather, we previously showed that FGFR2 M391R and FGFR2 Y381D initially promote osteoprogenitor cell proliferation, suggesting that p53 activation in this context does not interfere with proliferation (18). Here we found that p53 activation in response to nucleolar stress is associated with a severe delay in osteoblast differentiation, which is rescued by a chemical inhibitor of p53. p53 is a general regulator of cell differentiation that either promotes or represses differentiation, depending on the cell type (100). In osteoprogenitor cells, p53 inhibits differentiation in part through transcriptional repression of early osteogenic gene such as Osterix and Runx2 (31, 101) . This work helps to establish rDNA as developmentally regulated loci that receive direct input from FGF signaling to balance self-renewal and cell fate determination in osteoprogenitor cells. The FGFR2 mutations in BBDS augment epigenetic activation of rDNA, disrupt nucleolar structure, alter ribosome biogenesis, and activate the p53 the nucleolar stress response pathway. Aberrant activation of p53, in turn, blocks osteoblast differentiation. Drugs that reduce p53 activity are in development. Lenalidomide, which stabilizes MDM2 to promote p53 degradation, is being used as a promising therapeutic for the ribosomopathies Diamond-Blackfan anemia and 5q-syndrome (102) (103) (104) . Since p53 activation is mechanistically involved in BBDS, stabilizing Mdm2 with Lenalidomide is an exciting therapeutic option for this disorder. 
Materials and Methods
Cell culture
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed as previously described with slight modifications (18) . Briefly, cells were cross-linked, and nuclei isolated and sonicated to generate DNA fragments of $200 or $500 bp for histone marks or transcription factor ChIPs, respectively. Chromatin was diluted, and 10% of the supernatant was kept for input. The remainder of the supernatant was pre-cleared and incubated overnight with 5 lg of antibody followed by 4 h incubation with Protein G Dynabeads. Protein G bead complexes were washed, protein-associated chromatin was eluted, and cross-linking reversed. Chromatin was then purified and precipitated, and enriched DNA was quantified by qPCR using primers as listed in Supplementary Material, Table S1 . ChIP enrichment was determined as a percentage of the input. Antibodies used: anti-H3K14ac, antiH3K27ac, anti-H3K9me3, anti-H3K9me2, anti-HDAC1, anti-WSTF, anti-TBP (Abcam), anti-H4K4me3 and anti-H3K9ac (ActivMotif), anti-UBF1, anti-CSB, anti-POLR1D (Santa Cruz), anti-H3K27me3, anti-P300 (Millipore), and anti-H4K20me3 (Cell Signaling).
Nucleosome and DNA methylation sequencing analysis (NOMe-seq)
NOMe-seq assays were conducted as previously described (12, 40) . Briefly, cells were trypsinized and centrifuged for 5 min at 250g, then washed in ice-cold PBS, resuspended in 1 ml icecold lysis buffer (10 mM Tris, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 , 0.1 mM EDTA and 0.5% NP-40), and incubated on ice for 5 min. Nuclei were recovered by centrifugation for 5 min at 750g and washed in ice-cold wash buffer (10 mM Tris-HCl, pH 7.4, 10 mM NaCl, 3 mM MgCl 2 and 0.1 mM EDTA). Nuclei were resuspended in 1Â GpC buffer and incubated at 37 C in a reaction mixture of 1 M sucrose, 10Â GpC buffer, 32 mM SAM and 4 U/ll M.CviPI. Reactions were quenched with an equal volume of stop buffer (20 nM Tris-HCl, pH 7.9, 600 mM NaCl, 1% SDS, 10 mM EDTA, 400 mg/ml Proteinase K) and incubated overnight. DNA was purified by phenol-chloroform extraction and ethanol precipitation. Bisulfite conversion was performed using the EpiTect Bisulfite Kit (Qiagen 
Western blot analysis
Samples were resolved on a 10% SDS-PAGE gel, transferred to a nitrocellulose membrane, and probed with anti-P300 (Abcam, 1:1000) overnight at 4 C. Immunoreactivity was detected using a Phototope-HRP western blot detection system according to the manufacturer's instructions (Cell Signaling).
Polysome profiling
Polysome profiling was performed as previously described (12) . Briefly, MC3T3-E1 cells were treated with 200 lg/ml cyclohexamide for 20 min, washed, and scraped in PBS supplemented with 100 lg/ml cyclohexamide. Cells were counted and pellets resuspended in ice-cold lysis buffer (10 mM Tris-HCl, pH 7.4, 5 mM MgCl 2 , 100 mM KCl, 1% Triton X-100, 2 mM DTT, 20 U/ml Promega RNasin, 100 lg/ml cycloheximide, EDTA-free protease inhibitor) and incubated on ice for 10 min. Lysates were cleared at 10 000g at 4 C for 10 min. Supernatants were loaded onto 10-50% continuous sucrose gradients (20 mM HEPES-KOH, pH 7.4, 5 mM MgCl 2 , 100 mM KCl, 2 mM DTT, 20 U/ml Promega RNasin, 100 lg/ml cycloheximide) and centrifuged at 40 000 rpm for 2 h in a SW-41 Ti rotor (Beckman Coulter). Samples were then inserted into a tube piercer connected to a syringe pump (Brandel) and fractionated with an ISCO gradient fractionator/UA-6 detector system (Teledyne). Polysome profiles were recorded using WinDaq data acquisition software (DATAQ Instruments). Quantification of 40S, 60S, and 80S levels were determined from 4 biological replicates from each cell line by calculating corresponding peak areas of the gradient regions. The peak area under the curve was measured in Image J software using a pixel aspect ratio of 1 and the polygon selections tool to define boundaries (http://rsb.info.nih. gov/ij/index.html; date last accessed April 19, 2017) .
Differentiation assay by AP staining
MC3T3-E1 osteoprogenitors were grown to confluence followed by the addition of media containing ascorbic acid, b-glycerol phosphate, and doxycycline (Osteoinduction Differentiation Media; ODM) to induce differentiation. Fresh ODM was replaced every 3 days to promote mineralization during differentiation. After 6 days, cells were stained for AP as previously described (18) . Briefly, cells were washed with PBS, fixed with formalin, and then permeabilized with Triton X-100. Cells were stained for AP activity by incubation with NBT/BCIP substrate (Sigma 
Quantitative RT-PCR
RNA was isolated from cells using Trizol (ThermoFisher) and column purified with Direct-zol RNA MiniPrep Plus (Zymo Research). Total RNA levels were measured (NanoDrop), and 1 mg of RNA converted into cDNA by reverse transcription (ThermoFisher). qPCR from 100 ng of converted cDNA was performed with PerfeCta SYBR Green FastMix (Quanta Biosciences) using the primers listed in Supplementary Material, Table S1 .
Immunofluorescence
Cells were seeded on chamber slides (Lab-Tek), fixed in 4% paraformaldehyde, permeabilized, blocked, and incubated with anti-POL1RD (Santa Cruz, 1:500), anti-Mdm2 (Abcam, 1:100), anti-p53 (Santa Cruz, 1:100), or anti-Rpl11 (ProteinTech, 1:50) antibody overnight at 4 C. Primary antibodies were detected using Alexa
Fluor 568 conjugated goat anti-rabbit and/or Alexa Fluor 488 conjugated goat anti-mouse (Invitrogen) diluted 1:400 in 1% goat serum/PBS at room temperature for 1 h. Coverslips were mounted on slides using Vectashield with DAPI (Vector Laboratories). Images were captured using a Leica SP8 confocal microscope. Leica LAS X software was used to identify colocalized pixels, calculate signal intensities, and colocalization coefficients, and generate 3D renderings.
Statistical analysis
The Student t-test was used to test for significance in each set of values, assuming equal variance. Mean values plus or minus standard error of the mean (S.E.M.) are plotted. *P < 0.05, **P < 0.01.
Supplementary Material
Supplementary Material is available at HMG online.
